Open an account

Morphic Holding

MORF · NASDAQ

Price unavailable right now.

No price history for this range.

About MORF

Morphic Holding, Inc., operates as a biopharmaceutical company, which researches and develops oral small-molecule integrin therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 128 full-time employees. The firm is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The firm is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). The company has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.

Employees
128
Headquarters
Waltham, Massachusetts
Listed
Jun 27, 2019
Sector
Health Care
Industry
Biotechnology
Website
morphictx.com

MORF key statistics

This section is temporarily unavailable. Refresh to try again.

MORF earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 16.2% on average.

  1. Q3 FY22: reported -$0.78 per share against an estimate of -$0.8466
  2. Q4 FY22: reported -$0.64 per share against an estimate of -$0.8908
  3. Q1 FY23: reported -$0.90 per share against an estimate of -$0.8288
  4. Q2 FY23: reported -$0.92 per share against an estimate of -$0.8897
  5. Q3 FY23: reported -$0.73 per share against an estimate of -$0.9735
  6. Q4 FY23: reported -$0.96 per share against an estimate of -$0.8661
  7. Q1 FY24: reported -$0.91 per share against an estimate of -$0.9447
  8. Q2 FY24: reported -$1.15 per share against an estimate of -$0.9917

MORF news

  • Press releaseBusiness Wire

    Omega Funds Closes Oversubscribed $647 Million Fund VIII to Invest in Transformative Life Science Companies

  • Press releasePRNewswire

    Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease

  • Press releaseBusiness Wire

    Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RCM, DRQ, SSB, MORF on Behalf of Shareholders

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HMNF, MORF, BALY on Behalf of Shareholders

  • Press releasePRNewswire

    Kuehn Law Encourages MORF, PFC, WSBC, and ACNB Investors to Contact Law Firm

  • Press releaseBusiness Wire

    Calling All Morphic Holding, Inc. (MORF) Investors: Contact Bronstein, Gewirtz & Grossman, LLC To Claim Your Losses

  • Press releasePRNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHCR, MORF, BALY on Behalf of Shareholders

Similar companies

Companies in the same industry as Morphic Holding

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.